Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 27,500 shares, a decrease of 57.0% from the February 28th total of 63,900 shares. Based on an average daily volume of 284,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Oncotelic Therapeutics Stock Down 1.7 %

Oncotelic Therapeutics stock traded down $0.00 during trading hours on Friday, hitting $0.07. The company had a trading volume of 76,720 shares, compared to its average volume of 147,587. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.07. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01. The firm has a market capitalization of $27.95 million, a P/E ratio of -6.88 and a beta of -0.25. The firm’s fifty day moving average is $0.04 and its 200-day moving average is $0.03.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.